AbbVie Inc (ABBV.N)
45.25USD
4:04pm EDT
$-0.23 (-0.51%)
$45.48
$45.45
$45.89
$45.05
821,913
1,274,284
$47.99
$32.51
About
Overall
| Beta: | -- |
| Market Cap (Mil.): | $72,028.00 |
| Shares Outstanding (Mil.): | 1,583.73 |
| Dividend: | 0.40 |
| Yield (%): | 3.52 |
Financials
| ABBV.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 13.98 | 37.93 | 37.76 |
| EPS (TTM): | 3.25 | -- | -- |
| ROI: | -- | 19.48 | 18.76 |
| ROE: | -- | 20.17 | 19.59 |
Fast-growing Humira extends domination of AbbVie
- AbbVie Inc's reliance on its Humira arthritis drug became even more evident during the second quarter, when the product's sales jumped 12 percent and accounted for almost 56 percent of the U.S. drugmaker's revenue.
UPDATE 2-Fast-growing Humira extends domination of AbbVie
July 26 - AbbVie Inc's reliance on its Humira arthritis drug became even more evident during the second quarter, when the product's sales jumped 12 percent and accounted for almost 56 percent of the U.S. drugmaker's revenue.
FDA advisory panel votes against new use of AbbVie's Humira
- An advisory panel to the U.S. Food and Drug Administration voted against approving AbbVie Inc's rheumatoid arthritis drug Humira for treating an inflammatory disease of the spine.
FDA advisory panel votes against new use of AbbVie's Humira
July 23 - An advisory panel to the U.S. Food and Drug Administration voted against approving AbbVie Inc's rheumatoid arthritis drug Humira for treating an inflammatory disease of the spine.
BRIEF-Galapagos announces $50m extension to AbbVie deal
BRUSSELS, May 17 - Galapagos NV : * AbbVie and Galapagos extend GLPG0634 collaboration to include crohn's disease * Says AbbVie to pay Galapagos $50 million upon successful completion, expected
Abbvie says Chief Scientific Officer John Leonard to retire
- AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.
Abbvie says Chief Scientific Officer John Leonard to retire
May 10 - AbbVie Inc's chief scientific officer will be retiring in the next few months and will be involved in the process of naming a successor, the pharmaceutical company said in a regulatory filing on Friday.
AbbVie delivers on strong growth of Humira arthritis drug
- AbbVie Inc's quarterly profit rose 10 percent on surging sales of its Humira treatment for rheumatoid arthritis, and the company said it plans to launch several potentially lucrative new treatments for hepatitis C by early 2015.
UPDATE 3-AbbVie delivers on strong growth of Humira arthritis drug
April 26 - AbbVie Inc's quarterly profit rose 10 percent on surging sales of its Humira treatment for rheumatoid arthritis, and the company said it plans to launch several potentially lucrative new treatments for hepatitis C by early 2015.
AbbVie delivers on scorching Humira drug sales growth
- AbbVie Inc reported slightly better than expected quarterly results on Friday, fueled by surging sales of its Humira treatment for rheumatoid arthritis.
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$49.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$138.00
|
|
Provider: Validea
|
$12.00
|
|
Provider: Market Edge
|
$10.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

